<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20141209020258N187</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-07-19</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of tracheal tube cuff pressure balancing in preventing sore throat and hoarseness in general anesthesia using nitrous oxide in surgery in supine and prone positions</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of tracheal tube cuff pressure balancing in preventing sore throat and hoarseness in general anesthesia using nitrous oxide in surgery in supine and prone positions</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>212</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71194</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be allocated into 2 groups using a permuted balanced block randomization method with the size of blocks 8. Random sequence will be generated by an epidemiologist by running an online program in sealed envelope website (https://www.sealedenvelope.com/). Random chain concealment is done by opaque envelope method, Blinding description: In this study, the supervisor knows about the grouping and prescribes the drugs for the patients, and the specialized assistant does not know about the prescribed drugs, and the follow-up of the patients is with the anesthesiology resident, and the analyst does not know about the grouping, and as a result, the study will be double-blind.</study_design>
      <phase>3</phase>
      <hc_freetext>General anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed at appropriate times, also in the position group. Supine oxygen and N2O are prescribed with a concentration of 50:50. Intervention 2: Intervention group2 : The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed at appropriate times, also in the position group. Perone oxygen and N2O are prescribed with a concentration of 50:50. Intervention 3: control group1: The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed in appropriate timings as anesthesia maintenance. In the supine position group Oxygen and air are prescribed as 50:50. Intervention 4: control group 2: The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed at appropriate times, also in the position group. Peron oxygen and air are prescribed as 50:50.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Hesamedin Modir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr Hospital, Valiasr squre, Shahid Shirodi street</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3222 2003</telephone>
        <email>modir.he@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Esmaeel Moshiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr hospital, Shahid Shirodi street, Valiasr square</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3222 2003</telephone>
        <email>moshiri@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 30 to 60 years
ASA class I and II
No history of sore throat before surgery
No history of drug use
No history of chronic use of painkillers
Insensitivity to nitrous oxide
Failure to perform laparoscopic surgery
Absence of upper airway infection and colds
Absence of malampati more than 2
No need to use NG-tube during surgery and up to 24 hours after surgery
The duration of surgery should not be less than 60 minutes and not more than 120 minutes
Consent to participate in the study</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient's lack of consent to continue participating in the study
Observing blood during suction when removing the tracheal tube
For any reason, we have to perform laryngoscopy twice on the patient.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y48.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other and unspecified general anaesthetics</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed at appropriate times, also in the position group. Supine oxygen and N2O are prescribed with a concentration of 50:50.</i_keyword>
      <i_keyword>Intervention group2 : The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed at appropriate times, also in the position group. Perone oxygen and N2O are prescribed with a concentration of 50:50.</i_keyword>
      <i_keyword>control group1: The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed in appropriate timings as anesthesia maintenance. In the supine position group Oxygen and air are prescribed as 50:50.</i_keyword>
      <i_keyword>control group 2: The same tracheal tube from the same brand (flexicare, made in England) is used with a low pressure cuff (tracheal tube size 7-5/7 for women and 5/7-8 tracheal tube for men) Tracheal tube cuff using Ambu device cuff pressure gage and the water is inflated to a pressure of 25 cm, so that there is no audible air leakage at the maximum inspiratory pressure. The method of induction of general anesthesia is the same in all four groups, and isoflurane (0.5-1%) and Pofol infusion at a dose of 50-100 micrograms per kg per minute, and itracurium and fentanyl are prescribed at appropriate times, also in the position group. Peron oxygen and air are prescribed as 50:50.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sore throat. Timepoint: Recovery and 2, 4, 8, 12 and 24 hours after the operation. Method of measurement: Pain Visual Analog scale.</prim_outcome>
      <prim_outcome>Voice horsness. Timepoint: Recovery and 2, 4, 8, 12 and 24 hours after the operation. Method of measurement: Physical examination.</prim_outcome>
      <prim_outcome>Mean propofol consumption. Timepoint: End of study. Method of measurement: Physical examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-06</approval_date>
        <contact_name>Ethics comittee of Arak University of Medical Sciences</contact_name>
        <contact_address>Ethics comittee, Research center, Payambar Azam complex, Basij squre ,Sardasht,Arak Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
